8-BOC-3,8-二氮杂双环[3.2.1]辛烷 | 149771-44-8

• 物质功能分类: 有机原料 - 重氮、偶氮或氧化偶氮化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 8-BOC-3,8-二氮杂双环[3.2.1]辛烷
• 中文别名: 8-BOC-3,8-二氮杂双环[3.2.1]辛；8-Boc-3,8-二氮杂双环[3.2.1]辛烷；8-BOC-3,8-二氮杂二环[3.2.1]辛烷；3,8-二氮杂双环[3.2.1]辛烷-8-甲酸叔丁酯
• 英文名称: 8-t-butoxycarbonyl-3,8-diazabicyclo[3.2.1]octane
• 英文别名: tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate；3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester；8-Boc-3,8-diazabicyclo[3.2.1]octane；tert-butyl 3,8-diazacyclo[3.2.1]octane-8-carboxylate
• CAS: 149771-44-8
• 化学式: C₁₁H₂₀N₂O₂
• mdl: MFCD17016708
• 分子量: 212.292
• InChiKey: HNINFCBLGHCFOJ-UHFFFAOYSA-N

物化性质

• 沸点：
  295.4±15.0 °C(Predicted)
• 密度：
  1.076±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.909
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302+H312+H332,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 8-Boc-3,8-diaza-bicyclo[3.2.1]octane
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 8-Boc-3,8-diaza-bicyclo[3.2.1]octane
CAS number: 149771-44-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H20N2O2
Molecular weight: 212.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用

8-BOC-3,8-二氮杂双环[3.2.1]辛烷是一种有机合成中间体和医药中间体，广泛应用于实验室研发过程以及化工和医药生产中。

用途

8-BOC-3,8-二氮杂双环[3.2.1]辛烷主要用作有机合成和医药领域的中间体。

反应信息

• 作为反应物：
  描述：

  8-BOC-3,8-二氮杂双环[3.2.1]辛烷 在 盐酸 、 TEA 作用下， 以 乙醚 、 甲苯 为溶剂， 反应 2.5h， 生成 3-(6-Chloropyridazin-3-yl)-8-methyl-3,8-diazabicyclo[3.2.1]octane
  参考文献：
  名称：

  具烟碱活性的6-氯吡啶并氮杂-3-基衍生物：合成，结合和模型研究。

  摘要：

  在一个氮原子上被6取代的3,8-二氮杂双环[3.2.1]辛烷（1），2,5-二氮杂双环[2.2.1]庚烷（2），哌嗪（3）和高哌嗪（4）衍生物合成了-氯-3-哒嗪基，而另一个氮原子未被取代或被单或二甲基化，并测试了它们对神经元烟碱乙酰胆碱受体（nAChRs）的亲和力。所有化合物的K（i）值均在纳摩尔范围内。分子建模研究确定了其优选构象的位置，并使用连续溶剂模型在水中重新计算了它们的能量。一些化合物以其填充的构型显示，仅药效上的距离长于Sheridan模型对nAChRs受体考虑的值。从而，

  DOI：

  10.1021/jm0208830
• 作为产物：
  描述：

  3-苄基-8-(叔丁氧基羰基)-3,8-二氮杂双环[3.2.1]-辛烷 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 以95%的产率得到8-BOC-3,8-二氮杂双环[3.2.1]辛烷
  参考文献：
  名称：

  单取代和二取代的3,8-二氮杂双环[3.2.1]辛烷衍生物作为与依巴替丁结构相关的止痛药：合成，活性和建模。

  摘要：

  合成了一系列3,8-二氮杂双环[3.2.1]辛烷，它们在3位（化合物1）或8位（化合物2）被氯代杂芳基环取代，作为强效天然止痛剂Epibatidine的潜在类似物。当在热板试验中测试时，大多数化合物显示出显着效果，最有趣的是3-（6-氯-3-吡啶并嗪基）-3,8-二氮杂双环[3.2.1]辛烷（1a）。在1 mg / kg的皮下剂量下，1a导致疼痛阈值显着增加，其作用持续约45分钟。1a在小鼠腹部收缩试验中以5 mg / kg的剂量也表现出良好的保护作用，而在20 mg / kg的剂量下，它完全阻止了动物的收缩。纳洛酮（1 mg / kg腹膜内）的给药不会拮抗其抗伤害感受，而美加明（2 mg / kg腹膜内）则能拮抗其伤害感受，因此暗示烟碱系统参与其作用。结合研究证实了对α4 beta 2 nAChR亚型的高度亲和力（Ki = 4.1 +/- 0.21 nM）。对三种不同细胞系的nAChR功

  DOI：

  10.1021/jm970427p

文献信息

• BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas Operations, Inc.

  公开号：US20190300521A1

  公开（公告）日：2019-10-03

  The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为SMARCA2或BRM（靶蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端结合Von Hippel-Lindau E3泛素连接酶的配体，另一端结合靶蛋白的双功能化合物，使得靶蛋白与泛素连接酶靠近以实现靶蛋白的降解（和抑制）。本公开展示了与靶蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由靶蛋白聚集或积累导致的疾病或紊乱。
• [EN] 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS 2,3-DISUBSTITUÉS DE 1-ACYL-4-AMINO-1,2,3,4-TÉTRAHYDROQUINOLÉINE ET LEUR UTILISATION COMME INHIBITEURS DE BROMODOMAINES
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2014140076A1

  公开（公告）日：2014-09-18

  The present invention relates to novel compounds of formula (I), wherein R1 is C1-4alkyl; R2 is C1-4alkyl, C3-7cycloalkyl, -CH2CF3, -CH2OCH3 or heterocyclyl; R3 is C1-4alkyl, -CH2F, -CH2OH or -CH2O(O)CH3; R4 when present is as defined in claim 1; R5 when present is H, halo, hydroxy or C1-6alkoxy; A is -NH-, -O-, -S-, -SO-, -SO2-, -N(C1-4alkyl)- or -NC(O)(CH3)-; V is phenyl, heteroaromatic or pyridone any of which may be optionally substituted by 1, 2 or 3 substituents; W is CH or N; X is C or N; Y is C or N; and Z is CH or N; subject to the proviso that no more than 2 of W, X, Y and Z are N, pharmaceutical compositions containing such compounds and to their use as bromodomain inhibitors.

  本发明涉及式(I)的新化合物，其中R1为C1-4烷基；R2为C1-4烷基、C3-7环烷基、-CH2CF3、-CH2OCH3或杂环烷基；R3为C1-4烷基、-CH2F、-CH2OH或-CH2O(O)CH3；R4存在时如权利要求1所定义；R5存在时为H、卤素、羟基或C1-6烷氧基；A为-NH-、-O-、-S-、-SO-、-SO2-、-N(C1-4烷基)-或-NC(O)(CH3)-；V为苯基、杂芳基或吡啶酮，其中任何一个可以选择性地被1、2或3个取代基取代；W为CH或N；X为C或N；Y为C或N；Z为CH或N；但W、X、Y和Z中不超过2个为N，含有这种化合物的药物组合物以及它们作为溴结构域抑制剂的用途。
• THERAPEUTIC COMPOUNDS AND COMPOSITIONS
  申请人：Salituro Francesco G.

  公开号：US20120172349A1

  公开（公告）日：2012-07-05

  Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.

  本文描述了包含调节丙酮酸激酶M2（PKM2）的化合物和组合物。本文还描述了利用调节PKM2的化合物治疗癌症的方法。
• Pyruvate kinase activators for use in therapy
  申请人：Su Shin-San Michael

  公开号：US09404081B2

  公开（公告）日：2016-08-02

  Described herein are methods for using compounds that activate pyruvate kinase.

  这里描述了使用激活丙酮酸激酶的化合物的方法。
• PYRROLE mTORC INHIBITORS AND USES THEREOF
  申请人：Navitor Pharmaceuticals, Inc.

  公开号：US20190389843A1

  公开（公告）日：2019-12-26

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。